Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.
If approved, the test, called Shield, could become the second blood-based test for CRC screening in the United States after Epigenomics’ Epi proColon, which was approved in 2016.
Vaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and neck cancers and other malignancies, a new analysis shows, adding to the vaccine’s proven benefit in protecting women from cervical cancer.
Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron Therapeutics to develop novel therapies for oncology, neuroscience and inflammation.
The U.S. Court of Appeals for the District of Columbia on Tuesday ruled in favor of pharmaceutical companies, finding that drugmakers are allowed impose limits on the discounts that they may give under Section 340B of the Public Health Service Act.
Amid its ongoing efforts to trim $4 billion in spending in 2024, Pfizer in an SEC filing said it is looking to save an additional $1.5 billion over the next several years.